Triastek Partners with BioNTech to Develop 3D Printed Oral RNA Therapeutics
Shots:
- Triastek and BioNTech have entered into a research collaboration and platform technology license agreement for the development of oral RNA therapies using 3D printing technology
- The collaboration will utilize Triastek’s ability & knowledge to form innovative tablet structures such as multi-layer & multi-compartment designs using 3D printing to optimize the delivery of RNA therapies, ensuring its transfer to that part of gastrointestinal tract with greatest absorption
- BioNTech will pay $10M upfront and $1.2B development, regulatory & commercial milestones plus tiered royalties
Ref: Triastek | Image: Triastek & BioNTech
Related News: Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
